Cajal Neuroscience

About:

Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.

Website: https://cajalneuro.com

Twitter/X: CajalNeuro

Top Investors: Alexandria Venture Investments, Evotec, Bristol-Myers Squibb, Two Sigma Ventures, Lux Capital

Description:

Cajal Neuroscience is a biotechnology company integrating human genetics, functional genomics, and advanced microscopy to discover novel targets and therapeutics for neurodegeneration. The company combines a suite of state-of-the-art approaches and technologies, including integrative human genetics and multi-omics, high-throughput functional genomics, and advanced microscopy, to accelerate neurodegeneration target and drug discovery.

Total Funding Amount:

$96M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Seattle, Washington, United States

Founded Date:

2020-01-01

Contact Email:

info(AT)cajalneuro.com

Founders:

Alex Vaughan, Andrew Dervan, Charles Zuker, Huda Zoghbi, Ian Peikon, Robert M. Hershberg

Number of Employees:

51-100

Last Funding Date:

2022-11-29

IPO Status:

Private

Industries:

© 2025 bioDAO.ai